List of Chapters/Sections(Table Of Content)
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by PD-1& PD-L1 Inhibitor Revenue
1.4 Market Analysis by Type
1.4.1 Global PD-1& PD-L1 Inhibitor Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 PD-1 Inhibitor
1.4.3 PD-L1 Inhibitor
1.4.4 First-line Monotherapy
1.4.5 Second-line Monotherapy
1.4.6 First-line Combination Therapy
1.4.7 Second-line Combination Therapy
1.5 Market by Application
1.5.1 Global PD-1& PD-L1 Inhibitor Market Share by Application: 2022-2027
1.5.2 Non-small Cell Lung Cancer
1.5.3 Liver Cancer
1.5.4 Esophageal Cancer
1.5.5 Advanced Melanoma
1.5.6 Renal Cell Carcinoma
1.5.7 Bladder Cancer
1.5.8 Gastric Cancer
1.5.9 Non-small Cell Lung Cancer
1.5.10 Liver Cancer
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global PD-1& PD-L1 Inhibitor Market
1.8.1 Global PD-1& PD-L1 Inhibitor Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global PD-1& PD-L1 Inhibitor Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global PD-1& PD-L1 Inhibitor Revenue Market Share by Manufacturers (2016-2021)
2.3 Global PD-1& PD-L1 Inhibitor Average Price by Manufacturers (2016-2021)
2.4 Manufacturers PD-1& PD-L1 Inhibitor Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global PD-1& PD-L1 Inhibitor Sales Volume Market Share by Region (2016-2021)
3.2 Global PD-1& PD-L1 Inhibitor Sales Revenue Market Share by Region (2016-2021)
3.3 North America PD-1& PD-L1 Inhibitor Sales Volume
3.3.1 North America PD-1& PD-L1 Inhibitor Sales Volume Growth Rate (2016-2021)
3.3.2 North America PD-1& PD-L1 Inhibitor Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia PD-1& PD-L1 Inhibitor Sales Volume
3.4.1 East Asia PD-1& PD-L1 Inhibitor Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia PD-1& PD-L1 Inhibitor Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe PD-1& PD-L1 Inhibitor Sales Volume (2016-2021)
3.5.1 Europe PD-1& PD-L1 Inhibitor Sales Volume Growth Rate (2016-2021)
3.5.2 Europe PD-1& PD-L1 Inhibitor Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia PD-1& PD-L1 Inhibitor Sales Volume (2016-2021)
3.6.1 South Asia PD-1& PD-L1 Inhibitor Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia PD-1& PD-L1 Inhibitor Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia PD-1& PD-L1 Inhibitor Sales Volume (2016-2021)
3.7.1 Southeast Asia PD-1& PD-L1 Inhibitor Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia PD-1& PD-L1 Inhibitor Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East PD-1& PD-L1 Inhibitor Sales Volume (2016-2021)
3.8.1 Middle East PD-1& PD-L1 Inhibitor Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East PD-1& PD-L1 Inhibitor Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa PD-1& PD-L1 Inhibitor Sales Volume (2016-2021)
3.9.1 Africa PD-1& PD-L1 Inhibitor Sales Volume Growth Rate (2016-2021)
3.9.2 Africa PD-1& PD-L1 Inhibitor Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania PD-1& PD-L1 Inhibitor Sales Volume (2016-2021)
3.10.1 Oceania PD-1& PD-L1 Inhibitor Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania PD-1& PD-L1 Inhibitor Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America PD-1& PD-L1 Inhibitor Sales Volume (2016-2021)
3.11.1 South America PD-1& PD-L1 Inhibitor Sales Volume Growth Rate (2016-2021)
3.11.2 South America PD-1& PD-L1 Inhibitor Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World PD-1& PD-L1 Inhibitor Sales Volume (2016-2021)
3.12.1 Rest of the World PD-1& PD-L1 Inhibitor Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World PD-1& PD-L1 Inhibitor Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America PD-1& PD-L1 Inhibitor Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia PD-1& PD-L1 Inhibitor Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe PD-1& PD-L1 Inhibitor Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia PD-1& PD-L1 Inhibitor Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia PD-1& PD-L1 Inhibitor Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East PD-1& PD-L1 Inhibitor Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa PD-1& PD-L1 Inhibitor Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania PD-1& PD-L1 Inhibitor Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America PD-1& PD-L1 Inhibitor Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World PD-1& PD-L1 Inhibitor Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global PD-1& PD-L1 Inhibitor Sales Volume Market Share by Type (2016-2021)
14.2 Global PD-1& PD-L1 Inhibitor Sales Revenue Market Share by Type (2016-2021)
14.3 Global PD-1& PD-L1 Inhibitor Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global PD-1& PD-L1 Inhibitor Consumption Volume by Application (2016-2021)
15.2 Global PD-1& PD-L1 Inhibitor Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in PD-1& PD-L1 Inhibitor Business
16.1 Merck
16.1.1 Merck Company Profile
16.1.2 Merck PD-1& PD-L1 Inhibitor Product Specification
16.1.3 Merck PD-1& PD-L1 Inhibitor Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Bristol-Myers Squibb
16.2.1 Bristol-Myers Squibb Company Profile
16.2.2 Bristol-Myers Squibb PD-1& PD-L1 Inhibitor Product Specification
16.2.3 Bristol-Myers Squibb PD-1& PD-L1 Inhibitor Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Regeneron Pharmaceuticals
16.3.1 Regeneron Pharmaceuticals Company Profile
16.3.2 Regeneron Pharmaceuticals PD-1& PD-L1 Inhibitor Product Specification
16.3.3 Regeneron Pharmaceuticals PD-1& PD-L1 Inhibitor Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Roche
16.4.1 Roche Company Profile
16.4.2 Roche PD-1& PD-L1 Inhibitor Product Specification
16.4.3 Roche PD-1& PD-L1 Inhibitor Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Novartis
16.5.1 Novartis Company Profile
16.5.2 Novartis PD-1& PD-L1 Inhibitor Product Specification
16.5.3 Novartis PD-1& PD-L1 Inhibitor Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Jiangsu Hengrui Medicine
16.6.1 Jiangsu Hengrui Medicine Company Profile
16.6.2 Jiangsu Hengrui Medicine PD-1& PD-L1 Inhibitor Product Specification
16.6.3 Jiangsu Hengrui Medicine PD-1& PD-L1 Inhibitor Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Innovent Biologics
16.7.1 Innovent Biologics Company Profile
16.7.2 Innovent Biologics PD-1& PD-L1 Inhibitor Product Specification
16.7.3 Innovent Biologics PD-1& PD-L1 Inhibitor Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Shanghai Junshi Biosciences
16.8.1 Shanghai Junshi Biosciences Company Profile
16.8.2 Shanghai Junshi Biosciences PD-1& PD-L1 Inhibitor Product Specification
16.8.3 Shanghai Junshi Biosciences PD-1& PD-L1 Inhibitor Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 BeiGene
16.9.1 BeiGene Company Profile
16.9.2 BeiGene PD-1& PD-L1 Inhibitor Product Specification
16.9.3 BeiGene PD-1& PD-L1 Inhibitor Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.10 AstraZeneca
16.10.1 AstraZeneca Company Profile
16.10.2 AstraZeneca PD-1& PD-L1 Inhibitor Product Specification
16.10.3 AstraZeneca PD-1& PD-L1 Inhibitor Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.11 Pfizer
16.11.1 Pfizer Company Profile
16.11.2 Pfizer PD-1& PD-L1 Inhibitor Product Specification
16.11.3 Pfizer PD-1& PD-L1 Inhibitor Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 PD-1& PD-L1 Inhibitor Manufacturing Cost Analysis
17.1 PD-1& PD-L1 Inhibitor Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of PD-1& PD-L1 Inhibitor
17.4 PD-1& PD-L1 Inhibitor Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 PD-1& PD-L1 Inhibitor Distributors List
18.3 PD-1& PD-L1 Inhibitor Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of PD-1& PD-L1 Inhibitor (2022-2027)
20.2 Global Forecasted Revenue of PD-1& PD-L1 Inhibitor (2022-2027)
20.3 Global Forecasted Price of PD-1& PD-L1 Inhibitor (2016-2027)
20.4 Global Forecasted Production of PD-1& PD-L1 Inhibitor by Region (2022-2027)
20.4.1 North America PD-1& PD-L1 Inhibitor Production, Revenue Forecast (2022-2027)
20.4.2 East Asia PD-1& PD-L1 Inhibitor Production, Revenue Forecast (2022-2027)
20.4.3 Europe PD-1& PD-L1 Inhibitor Production, Revenue Forecast (2022-2027)
20.4.4 South Asia PD-1& PD-L1 Inhibitor Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia PD-1& PD-L1 Inhibitor Production, Revenue Forecast (2022-2027)
20.4.6 Middle East PD-1& PD-L1 Inhibitor Production, Revenue Forecast (2022-2027)
20.4.7 Africa PD-1& PD-L1 Inhibitor Production, Revenue Forecast (2022-2027)
20.4.8 Oceania PD-1& PD-L1 Inhibitor Production, Revenue Forecast (2022-2027)
20.4.9 South America PD-1& PD-L1 Inhibitor Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World PD-1& PD-L1 Inhibitor Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of PD-1& PD-L1 Inhibitor by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of PD-1& PD-L1 Inhibitor by Country
21.2 East Asia Market Forecasted Consumption of PD-1& PD-L1 Inhibitor by Country
21.3 Europe Market Forecasted Consumption of PD-1& PD-L1 Inhibitor by Countriy
21.4 South Asia Forecasted Consumption of PD-1& PD-L1 Inhibitor by Country
21.5 Southeast Asia Forecasted Consumption of PD-1& PD-L1 Inhibitor by Country
21.6 Middle East Forecasted Consumption of PD-1& PD-L1 Inhibitor by Country
21.7 Africa Forecasted Consumption of PD-1& PD-L1 Inhibitor by Country
21.8 Oceania Forecasted Consumption of PD-1& PD-L1 Inhibitor by Country
21.9 South America Forecasted Consumption of PD-1& PD-L1 Inhibitor by Country
21.10 Rest of the world Forecasted Consumption of PD-1& PD-L1 Inhibitor by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
